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for De Novo Stenosis
The Balloon is Back.Reloaded!*Robert A. Byrne, MB, BCH, PHD,y Michael Joner, MDyzI t seems obvious to many of us that if a stenosiscould be effectively treated by angioplasty alonerather than stent implantation, this would be the
best option over the long-term. Writing in Circulation
in 1998 in a paper subtitled, “the balloon is back!”
some experts called for a change of course away
from routine stent implantation during percutaneous
coronary intervention, advocating instead a strategy
of systematic aggressive balloon angioplasty with
provisional stent implantation when required (1).
Ultimately, it was maintained, clear evidence should
be generated that an alternative approach is superior
before optimized angioplasty with provisional stent-
ing should be abandoned. The passage of time has
seen routine stent implantation supplant angioplasty
as the default strategy for percutaneous coronary
intervention. Nowadays, if a lesion can be stented,
it usually is. So, why has the pursuit of balloon angio-
plasty been a vain undertaking? The reasons are not
difﬁcult to understand.
First, angioplasty alone results in varying degrees
of vessel wall injury, ranging from intimal tears to
frank medial dissection. Accordingly, a subset of
treated patients is at risk of abrupt vessel closure.
Routine stenting, however, seals dissections and ﬂaps*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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W.L. Gore.resulting in more predictable acute results. Second,
vessel recoil and constrictive remodeling are domi-
nant causes of restenosis after angioplasty. Routine
stenting addresses both issues and results in greater
acute gain and lower risk of subsequent restenosis
compared with angioplasty alone. In addition, the
advent of drug-eluting stent (DES) technology has
almost eliminated the secondary problem of in-stent
restenosis due to neointimal hyperplasia. Third, the
proliferation of high-performance “me too” DES de-
vices has driven the cost of stent technology down-
ward to the point where unit cost in certain countries
already approaches the $100 mark. This means that
ﬁnancial disincentives for stent implantation are
increasingly less relevant. The rapid progress in stent
technological development and the continual im-
provement in patient outcomes meant that further
large-scale clinical trials investigating optimized an-
gioplasty with provisional stent implantation were
never performed, due to a perceived lack of clinical
equipoise compared with routine stenting.
Drug-coated balloons are standard angioplasty
catheters that are surface coated with active drug
mixed with a spacer (or excipient) that facilitates
transfer of the drug to the vessel wall (2). So, should
we expect the fate of angioplasty with drug-coated
balloons to be much better than that of its predeces-
sor, plain balloon angioplasty? There are at least 2
reasons to believe that it might. First, the advent
of effective dual antiplatelet therapy has been central
to the success of contemporary percutaneous inter-
vention (3), and current antiplatelet regimens are
well-established and effective. This means that
abrupt vessel closure after drug-coated balloon an-
gioplasty in the setting of vessel wall dissection is
likely to be less of an issue. Second, in common with
DES therapy, angioplasty with drug-coated balloons
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2011effectively targets neointimal hyperplasia and in-
hibits restenosis. Pre-clinical experience and clinical
trials clearly show that a brief dilation (of just 30 to 60
s duration) can produce effective drug transfer as well
as durable inhibition of restenosis (2).SEE PAGE 2003In this issue of JACC: Cardiovascular Interventions,
Cortese et al. (4) study the outcome of 156 patients
with de novo stenosis treated with drug-coated
balloon angioplasty who underwent angiographic
surveillance approximately 6 months after interven-
tion. At the outset, only one-third (n ¼ 52) had
angiographic evidence of dissection after angioplasty,
and most of these were classiﬁed as mild to moderate
(n ¼ 48) (type A to C according to National Heart,
Lung, and Blood Institute deﬁnitions [5]). Accord-
ingly, these were deemed not to require treatment.
The main ﬁnding of the study was that the fate of
these patients was encouraging, with a benign clinical
course and a favorable appearance at surveillance
angiography. Patients with severe or ﬂow-limiting
dissection (type D to F according to National Heart,
Lung, and Blood Institute deﬁnitions [5]) following
angioplasty were not considered for further angio-
graphic analysis: every interventionalist knows that
these patients must be treated promptly with stenting
to ensure a favorable clinical course.
The observations of Cortese et al. (4) are important
and reinforce the impression from trials of plain
balloon angioplasty that mild to moderate dissection
is associated with a benign clinical course (6,7).
However, there are some important limitations that
should be considered when interpreting the results.
First and most importantly, although easy to use,
angiography alone is a blunt tool for assessing coro-
nary dissection. By pathology, dissections are
deﬁned as a separation of the intima/media from the
underlying adventitia including a dissecting hemor-
rhage. It seems intuitive that the prognosis of “true”
medial dissections is substantially different from
intimal tears and ﬂaps. However, it is likely not ideal
to rely on an angiography-based system to classify
and triage patients to provisional stent implantation.
In this respect, the current study was underpowered
to provide meaningful information on adverse clin-
ical events, so caution must be exercised in inter-
preting the outcome data. Intravascular imaging
modalities, such as optical coherence tomography or
intravascular ultrasound, have higher sensitivity in
detecting and classifying dissection and should be
preferred (8). Second, the external validity of the
data is limited due to the recruitment of selected
patients at just 2 centers and the exclusion ofpatients with lesions in heavily calciﬁed vessels or
vessels >3 mm in diameter. Third, the angiographic
data presented was not analyzed in a core laboratory.
This affects internal validity. Finally, some of the
authors’ interpretations are open to question. In
particular, the claim that paclitaxel release from
drug-coated balloon angioplasty may facilitate vessel
healing is speculative. In fact, our experience in an-
imal studies suggested that successful drug transfer
was almost invariably associated with features of
delayed arterial healing characterized by loss of
smooth muscle cells within the intima and media,
prolonged ﬁbrin deposition, and inﬂammation (2,9).
So, what is the future for drug-coated balloon
angioplasty for de novo coronary disease? Although a
strategy of optimized angioplasty with liberal use of
intravascular imaging and provisional stenting holds
promise, some skepticism persists. Despite many
years of clinical experience with drug-coated balloons
in certain parts of the world, its use in routine prac-
tice is not widespread. Most encouraging comparative
efﬁcacy data against DES is limited to studies
enrolling patients with in-stent restenosis (10). In
fact, the use of drug-coated balloon angioplasty for
treatment of de novo stenosis is mostly restricted to
selected enthusiastic adopters, and current clinical
practice guidelines do not support their use for this
indication (11). Two barriers in particular hinder more
widespread adoption of this therapy. The ﬁrst is the
excellent clinical outcome seen with current-
generation DES based on their thinner stent struts
and lower metal footprint. This is nicely illustrated in
a systematic review of coronary stent data from 158
trials by a recent stent task force. In this analysis, at 9
to 12 months, the median rates of repeat revascular-
ization in studies with new-generation DES was 2.91%
(interquartile range [IQR]: 1.67% to 5.94%), and the
rate of stent thrombosis was only 0.47% (IQR: 0.28%
to 0.72%) (12). The second is the considerable in-
vestment in bioresorbable stent technology as a
means to improving late outcomes (13). Although
bioresorbable stents might be considered a work-in-
progress, iterative development of these devices will
likely reduce opportunities for drug-coated balloon
angioplasty in the future (14).
Ultimately, the ﬁndings of Cortese et al. (4) should
provide an impetus for investment in further ran-
domized clinical trials investigating angioplasty with
drug-coated balloons. However, in exploring the late
beneﬁts of stentless technologies in clinical practice,
we must not surrender the predictable acute results
and the excellent midterm outcomes that we and
our patients have come to expect with current-
generation DES devices. For this reason, disruptive
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2012technology such as drug-coated balloon angioplasty
must be subject to clinical testing with the tools and
techniques we know best. This requires random
treatment allocation, sufﬁcient statistical power to
reliably detect superiority or noninferiority against
DES, and the use of clinical endpoints accepted by
academic and regulatory authorities. In the absence
of such trials, it is difﬁcult to envisage that thecall “the balloon is back!” will gain widespread
support in the contemporary era of percutaneous
intervention.
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